S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014|
|Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets|
|FDA Approves AstraZeneca, Nektar Constipation Drug--Update (2014/9/16)|
|Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation|
|FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain|
|Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting|
|Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients|
|Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer|
|FDA Approves MOVANTIK™ (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain|
|StemCells, Inc. Strengthens Senior Executive Team|
Click above to view more mutual fund data and stats for nktr - Nektar Therapeutics Inc.